胃癌患者外周血T细胞免疫球蛋白黏蛋白-3的表达及临床意义

doi:10.3877/cma.j.issn.1674-0785.2021.08.012

目的

探讨胃癌患者外周血T细胞T细胞免疫球蛋白黏蛋白-3（Tim-3）的表达及临床意义。

方法

收集2019年5月至2020年4月郑州大学第五附属医院45例胃癌患者的外周静脉血，同时收集23名健康人外周静脉血。流式细胞术检测45例胃癌患者及23名健康人外周血中Tim-3的表达，检测胃癌患者外周血Tim-3阳性及Tim-3阴性T细胞早期凋亡分子和内因子的表达水平，分析胃癌患者Tim-3表达与临床病理参数及幽门螺杆菌感染情况的关系。

结果

与健康志愿者比较，Tim-3在胃癌患者外周血T细胞中表达水平较高［（13.349±3.025）% vs （5.520±1.771）%，P＜0.001］。Tim-3⁺T细胞相比Tim-3^-T细胞分泌γ干扰素（INF-γ）能力减弱［（16.395±2.568）% vs （27.150±3.113）%，P＜0.001］，凋亡增多［（24.127±3.822）% vs（11.259±2.520）%，P＜0.001］。相比分期为Ⅰ~Ⅱ期的胃癌患者，分期为Ⅲ~Ⅳ期的患者外周血T细胞Tim-3表达水平明显升高［（14.463±2.951）% vs （11.515±2.175），P=0.001］；外周血T细胞Tim-3的表达与幽门螺杆菌感染无明显相关（P＞0.05）。

结论

胃癌患者T细胞中Tim-3高表达，导致T细胞功能耗竭，晚期胃癌患者Tim-3表达水平更高，可作为胃癌的有效治疗靶点。

关键词: 胃癌, T细胞免疫球蛋白黏蛋白-3, T细胞, 免疫检查点

Objective

To evaluate the clinical significance of expression of T cell immunoglobulin and mucin-domain-containing molecule-3 (Tim-3) in peripheral blood T cells of patients with gastric cancer.

Methods

Peripheral blood samples were collected from 45 patients with gastric cancer in the Fifth Affiliated Hospital of Zhengzhou University from May 2019 to April 2020. Peripheral blood samples from 23 healthy volunteers were also collected during the same time period. The expressions of Tim-3 in the peripheral blood samples of gastric cancer patients and healthy volunteers were detected by flow cytometry. Early apoptotic signaling molecules and intrinsic factors in peripheral blood with Tim-3⁺ T cells or Tim-3^- T cells were determined by flow cytometry. Also, the correlation between Tim-3 T cell expression with pathological parameters and Helicobacter pylori infection status was investigated.

Results

Compared with healthy volunteers, Tim-3 expression in T cells was higher in peripheral blood of gastric cancer patients [(13.349±3.025)% vs (5.520±1.771)%, P＜0.001]. Compared with Tim-3^- T cells, Tim-3⁺ T cells had less secreted interferon-γ [(16.395±2.568]% vs (27.150±3.113)%, P＜0.001] and increased apoptosis [(24.127±3.822)% vs (11.259±2.520)%, P＜0.001]. Compared with patients with stage Ⅰ/Ⅱ gastric cancer, the expression level of Tim-3 in peripheral blood T cells of patients with stage Ⅲ/Ⅳ gastric cancer was significantly higher [(14.463±2.951)% vs (11.515±2.175), P=0.001], but the expression of Tim-3 in peripheral blood T cells was not significant associated with Helicobacter pylori infection (P＞0.05).

Conclusion

Patients with gastric cancer have higher Tim-3 expression, which can induce T cell dysfunction. And the expression level of Tim-3 in advanced gastric cancer is even higher, suggesting that Tim-3 may serve as a potential therapeutic target for gastric cancer.

Key words: Gastric cancer, T cell immunoglobulin and mucin-domain-containing molecule-3, T cells, Immune checkpoint

图1 T细胞免疫球蛋白黏蛋白（Tim）-3在胃癌患者及健康志愿者外周血T细胞表面的表达情况图a为胃癌患者流式图；图b为健康志愿者流式图

图2 胃癌患者外周血T细胞干扰素（IFN）-γ分泌情况。左象限为Tim-3^-细胞群，其中，左上象限为IFN-γ⁺的Tim-3^-T细胞，左下象限为IFN-γ^-的Tim-3^-T细胞；右象限为Tim-3⁺细胞群，其中，右上象限为IFN-γ⁺的Tim-3⁺T细胞，右下象限为IFN-γ^-的Tim-3⁺T细胞注：Tim-3为T细胞免疫球蛋白黏蛋白-3

图3 胃癌患者外周血T细胞凋亡情况。左象限为Tim-3^-细胞群，其中，左上象限为Annexin Ⅴ⁺的Tim-3^-T细胞，左下象限为Annexin Ⅴ^-的Tim-3^-T细胞；右象限为Tim-3⁺细胞群，其中，右上象限为Annexin Ⅴ⁺的Tim-3⁺T细胞，右下象限为Annexin Ⅴ^-的Tim-3⁺T细胞注：Tim-3为T细胞免疫球蛋白黏蛋白-3

表1 胃癌患者外周血T细胞T细胞免疫球蛋白黏蛋白（Tim）-3的表达与临床病理参数的关系（%，

x ˉ

±s）

项目	例数	Tim-3表达水平	t值	P值
性别			0.272	0.787
男	28	13.446±2.662
女	17	13.190±3.629
年龄（岁）			-0.038	0.970
≤50	14	13.375±2.529
＞50	31	13.338±3.264
分化程度			0.693	0.492
高中分化	30	13.572±3.049
低分化	15	12.905±3.031
临床分期			-3.566	0.001
Ⅰ~Ⅱ期	17	11.515±2.175
Ⅲ~Ⅳ期	28	14.463±2.951
幽门螺杆菌感染			11.807	0.078
有	27	13.998±3.391
无	18	12.376±2.106

表1 胃癌患者外周血T细胞T细胞免疫球蛋白黏蛋白（Tim）-3的表达与临床病理参数的关系（%，

x ˉ

±s）

项目	例数	Tim-3表达水平	t值	P值
性别			0.272	0.787
男	28	13.446±2.662
女	17	13.190±3.629
年龄（岁）			-0.038	0.970
≤50	14	13.375±2.529
＞50	31	13.338±3.264
分化程度			0.693	0.492
高中分化	30	13.572±3.049
低分化	15	12.905±3.031
临床分期			-3.566	0.001
Ⅰ~Ⅱ期	17	11.515±2.175
Ⅲ~Ⅳ期	28	14.463±2.951
幽门螺杆菌感染			11.807	0.078
有	27	13.998±3.391
无	18	12.376±2.106

1	Rebecca L,Kimberly D. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 8(2): 145-164.
2	Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease [J]. Nature, 2002, 415(6871): 536-541.
3	Grabmeier-pfistershammer K, Stecher C, Zettl M, et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade [J]. Clin Immunol, 2017, 183(2): 167-173.
4	Gefen T, Castro I, Muharemagic D, et al. A TIM-3 oligo-nucleotide aptamer enhances T cell functions and potentiates tumor immunity in mice [J]. Mol Ther, 2017, 25(10): 2280-2288.
5	Mckinney EF, Smith KG. T cell exhaustion and immune-mediated disease-the potential for thera- peutic exhaustion [J]. Curr Opin Immunol, 2016, 43(1): 74-80.
6	Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised ,open-label phase 2 trial [J]. Lancet Oncol, 2018, 19(7): 940-952.
7	Segal NH, Ou SI, Balmanoukian A, et al. Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort [J]. Eur J Cancer, 2019, 109: 154-161.
8	Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma (ES-CORT): a multicentre, randomized, open-label, phase 3 study [J]. Lancet Oncol, 2020, 21(6): 832-842.
9	Tabernero J, Van Cutsem E, Bang Y, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase 3 KEYNOTE-062 study [J]. Ann Oncol, 2019, 30(Suppl 4): iv152-iv153.
10	Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomized, phase 3 trial [J]. Lancet Oncol, 2018, 19(11): 1480-1492.
11	Schmid P, Adams S, Rugo HS, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer [J]. N Engl J Med, 2018, 379(22): 2108-2121.
12	Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co- inhibitory receptors with specialized functions in immune regulation [J]. Immunity, 2016, 44(5): 989-1004.
13	Gao J, Qiu X, Li X, et al. Expression profiles and clinical value of plasma exosomal Tim-3 and Galectin-9 in non-small cell lung cancer [J]. Biochem Biophys Res Commun, 2018, 498(3): 409-415.
14	Granier C, Dariane C, Combe P, et al. Tim-3 expression on tumor infiltrating PD-1(+) CD8(+) T Cells correlates with poor clinical outcome in renal cell carcinoma [J]. Cancer Res, 2017, 77(5): 1075-1082.
15	Li F, Li N, Sang J, et al. Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepato-cellular carcinoma patients in chronic hepatitis B virus infection [J]. Cancer Manag Res, 2018, 10(11): 941-951.
16	Yu JT, Zhang HH, Sun SB, et al. The effects of Tim-3 activation on T-cells in gastric cancer progression [J]. Oncol Lett, 2019, 17(2): 1461-1466.
17	Wang Y, Zhao E, Zhang Z, et al. Association between Tim-3 and Gal-9 expression gastric cancer prognosis [J]. Oncol Rep, 2018, 40(4): 2115-2126.
18	Zhou G, Sprengers D, Boor PPC, et al. Antibodies against immune checkpoint molecules restore functions of tumor-infiltrating T cells in hepatocellular carcinomas [J]. Gastroenterology, 2017, 153(4): 1107-1110.
19	Wang F, Mao Z, Liu D, et al. Overexpression of Tim-3 reduces Helicobacter pylori-associated inflammation through TLR4/NFkappaB signaling in vitro [J]. Mol Med Rep, 2017, 15(5): 3252-3258.
20	Naghavi-Alhosseini M, Tehrani M, Ajami A, et al. Tim-3 up-regulation in patients with gastric cancer and peptic ulcer disease [J]. Asian Pac J Cancer Prev, 2017, 18(3): 765-770.

[1]	汤宏涛, 何坤. 中晚期肝细胞癌介入治疗的进展及前景[J/OL]. 中华普通外科学文献(电子版), 2024, 18(04): 305-308.
[2]	李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[3]	黄一博, 李至彦, 林晨, 陶亮, 王萌, 管文贤. 胃癌根治术中淋巴结示踪剂的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 586-588.
[4]	郭倩男, 史嘉玮, 董念国. T细胞不同代谢方式在移植排斥反应中的研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18(05): 315-320.
[5]	郑琪, 马婕群, 张彦兵, 廖子君, 张锐. EPHA5突变预测肺腺癌免疫检查点抑制剂治疗预后的临床意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 548-552.
[6]	陈冬丽, 邓迎丽, 毕婧. α-干扰素治疗急性呼吸道病毒感染对Th1/Th2平衡及肺功能的影响[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(04): 590-594.
[7]	王鹏, 邵欣欣, 胡海涛, 田艳涛, 钟宇新. 改良MOBS 吻合法在全腹腔镜近端胃大部分切除中的应用[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 267-270.
[8]	胡海涛, 邵欣欣, 姜玉娟, 王鹏, 李维坤, 卢一鸣, 田艳涛. 十二指肠残端处理对全腹腔镜胃癌根治术后并发症的影响[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(04): 205-209.
[9]	王泽钦, 洪军, 王雅平, 王健, 蒿汉坤. W型肝脏悬吊技术在全腹腔镜下全胃切除术中的应用[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(04): 218-221.
[10]	刘先勇, 秦东梅, 张若梅, 李俊娇, 孟春芹, 邬明歆, 王玉红, 赵新鲜, 徐瑞联, 洪文文, 马玲, 仇玮, 周宇. Her2/Hes1在肠型胃癌Correa级联反应3个病理阶段中的表达及意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 321-327.
[11]	陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12]	张英信, 林婷, 张剑文. 构建靶向HLA-A2且表达PD-L1的CAR-Treg细胞及验证其对CD4⁺T细胞抑制作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 719-728.
[13]	孙婧婷, 李娜, 罗明辉, 高瑶瑶, 白义行, 朱国贞. 短链脂肪酸对小鼠缺血再灌注肾损伤的炎症及纤维化影响和作用机制研究[J/OL]. 中华肾病研究电子杂志, 2024, 13(04): 181-187.
[14]	杨智钧, 谷佳, 丁聿贤, 张正奎, 于如同. 脑胶质瘤患者血清炎性因子水平与病理分级及预后的相关性[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(04): 238-242.
[15]	甘曦, 廖鑫. 胃癌旁肿瘤沉积与CT影像学特征、血清指标及病理特征的关联性分析[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 422-425.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of expression of T cell immunoglobulin and mucin-domain-containing molecule-3 in peripheral blood T cells of patients with gastric cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Clinical significance of expression of T cell immunoglobulin and mucin-domain-containing molecule-3 in peripheral blood T cells of patients with gastric cancer